@airo_young

Young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) represents the young radiotherapy community in Italy

Joined May 2021
  • Tweets208
  • Following107
  • Followers273
50Media
If he had gotten SBRT, he would have left 5 minutes after the procedure…. Just saying….
Dr. Estela Rodriguez
@LatinamdOct 17
It’s lovely to see @Pontifex leaving the hospital POD#4 after having lung cancer surgery 🫁 on Tuesday. Praying for his fast recovery ( FYI: most patients that undergo robotic lung surgery do leave the hospital within days- surgical techniques have improved)
6
5
2
55
47,608
#ASTRO26 PACE-A: 8-year results 🧠 SBRT vs prostatectomy in localized prostate cancer: ☢️ 8-y BCF-free: 91.2% vs 83.7% 🚻 ≥1 urinary pad: 8.3% vs 48% 🦠 Moderate/big bowel problems: 0% vs 3.6% ⚕️ Grade ≥2 GU toxicity: 3.8% vs 2.5% #ProstateCancer #SBRT #RadiationOncology
🤖 Made with AI
5
60
122
7,790
Prostate cancer paper of the day WOLVERINE — metastasis-directed therapy in oligometastatic #prostatecancer (@TheLancetOncol, Feb 2026) IPD meta-analysis of phase 2 RCTs (7 trials, n=574; MDT+SOC vs SOC primary set n=472) • PFS: HR 0.45 (patient-level) • Radiographic PFS: HR 0.59 • Castration-resistance–free survival: HR 0.58 • OS: HR 0.64 (not statistically significant) Takeaway: MDT improves disease-control endpoints in oligometastatic disease across trials. Caveat: OS still unproven — more mature data needed. doi.org/10.1016/S1470-2045(2…
1
11
1
54
5,296
Amici radio‑oncologi👋🏼 con i colleghi del Gruppo GU AIRO, abbiamo preparato una survey sulla recidiva biochimica post-prostatectomia, per arrivare a pillole pratiche condivise su necessità reali💊🎯 ⏳Servono solo 5 minuti surveymonkey.com/r/Recidiva-… #PCa #bcr #RadOnc #survey
2
4
13
631
#WorldRadiotherapyAwarenessDay 🧡
Andrea D'Aviero@AndreaDav89Sep 7
Today, 7 September, we celebrate #WorldRadiotherapyAwarenessDay. 🌍🧡 #Radiotherapy is a cornerstone of #cancercare, yet access remains unequal worldwide. Let’s raise #awareness and #support equitable access to safe, effective and modern radiotherapy for every patient.
1
2
107
Today, 7 September, we celebrate #WorldRadiotherapyAwarenessDay. 🌍🧡 #Radiotherapy is a cornerstone of #cancercare, yet access remains unequal worldwide. Let’s raise #awareness and #support equitable access to safe, effective and modern radiotherapy for every patient.
🤖 Made with AI
3
1
7
380
🚨 Excited to share that registration is now open for the 2nd International Multidisciplinary Consensus on the Integration of RT with Systemic Treatments 📍 Florence 📅 9–10 Oct 2026 ✅ Free registration ⚠️ Limited spots available #FlorenceConsensus26 @airo_young
Icro Meattini@Icro_MeattiniJul 10
🚨 Registration OPEN! clinicaloncology.events/ Join the 2nd International Multidisciplinary Consensus on the Integration of RT with Systemic Treatments #FlorenceConsensus26 Florence 🇮🇹 9–10 Oct 2026 ✅ FREE registration ⚠️ 100 spots – first come, first served! @OncoAlert
3
7
1,372
One of #radonc oldest dogmas: No full bladder, no treatment. Countless patients have spent years anxiously drinking water, waiting, and hoping they got it "just right." We asked a simple question: Do we really need a full bladder for prostate SBRT?
8
64
8
187
23,182
“How to’ do SBRT in prostate cancer” consensus recommendations is to define minimum requirements, common practices and additional options for prostate SBRT based on scientific evidence, expert opinion and consensus. @RO_GreenJournal @ESTRO_RT Read it 👉 thegreenjournal.com/article/…
1
49
92
4,717
youngAIRO retweeted
Shankar Siva
@_ShankarSivaJun 3
This is so cool!!! Thanks @TheLancetOncol #radonc
Muhammad Ali
@dr_alimuhammadJun 2
Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years. thelancet.com/journals/lanon…
7
38
208
18,633
Replying to @HimanshuNagarMD @DrSpratticus @seanmmcbride
A perfect example of where beautiful dosimetric arguments do not pan out for patient benefit. Hence, we run trials. And maybe we should reconsider dosimetry. I’m sure it matters! But we may be focusing on the wrong metrics. @NehaVapiwala @CZamboglou @alison_tree
1
6
1
19
3,894
Now we have PARTIQoL and COMPPARE….message is quite clear as to if there is any benefit of protons for localized prostate cancer. @DrSpratticus @seanmmcbride @TylerSbrt
Toni Choueiri, MD
@DrChoueiriMay 31
Kicking off the GU Rapid Oral Session at #ASCO26, #NancyMendenhall presents early results from COMPPARE, showing comparable bowel outcomes, grade ≥2 GI toxicity (5.2% vs 5.6%), and 3-year FFBP (98.0% vs 97.9%) in LPC. #ASCO26 #ProstateCancer @ASCO @OncoAlert
4
12
2
26
11,902
Ieri, presso la Camera dei Deputati, durante la II edizione degli Stati Generali della Radioterapia Oncologica promossa da #AIRO, il confronto si è concentrato su formazione, innovazione e futuro! Come #AIROGiovani, abbiamo partecipato attivamente! #RadOncs4Life
7
8
293
Stati Generali della Radioterapia Oncologica, dalla Camera dei Deputati il confronto sul futuro delle cure contro il cancro @airo_young 👉 takethedate.it/approfondimen…
1
1
32
Huge congratulations to our #ESTRO President @BarbaraJereczek 🎉🎉🎉 we stand with you 🙌 @ESTRO_RT — wishing you a luminous and inspiring presidency ahead! @peppinoiorio @S_GreyParisi @GrassiRoberta89 @AndreaDav89
5
11
465
This is @ESTRO_org here in Stockholm: a Swiss 🇨🇭, two Italians 🇮🇹, a Canadian 🇨🇦 (able also to speak 🗣️ Italian better than my English!). Several amazing combos of Radoncs every time!! #ESTRO26
10
54
1,954
Miami HEAT Trial, interim primary results at @ESTRO_RT #ESTRO2026 remarkable data and superb presentation by @c_abramowitz and David J.Lee! Fantastic collaborative effort 🇺🇸 🇮🇹 🇦🇺! Proud to be part of this great Team #UmbertoRicardi @SylvesterCancer @umiamimedicine @UMiamiHealth
1
9
1
11
838
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging). Twittorial below Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)... 1/n
7
85
5
151
18,249
📣 #ESTRO26 - @UmbertoRicardo e2irradiate @EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets. ➡️ local failure 5% at 1 year and 11% at 3 years ➡️ Colorectal cancer has higher risk of progression ➡️ minimum PTV dose correlated with outcome We should aim to deliver high quality SABR to optimise control! #radonc
2
51
4
103
11,572
youngAIRO retweeted
Piet Ost@piet_ostMay 17
🔬 PEACE 2 phase III: Adding pelvic RT to prostate RT + 3y ADT in very high-risk localized prostate cancer did NOT improve bPFS, MFS, CSS or OS. Borderline cPFS signal (HR 0.81, p=0.09). No added AEs. @PBlanchard_MD #ESTRO2026. @VedangMurthy what now?
6
60
2
137
10,532
Load more